Drospirenone-containing oral contraceptives and risk of adverse outcomes after myocardial infarction

Keyphrases

• Myocardial Infarction 100%
• Adverse Outcomes 100%
• Oral Contraceptives 100%
• Drospirenone 100%
• Yasmin 50%
• 50 Years Old 25%
• Thrombus Burden 25%
• ST-elevation Myocardial Infarction (STEMI) 16%
• Post-procedural 16%
• ST-segment Resolution 16%
• Primary Angioplasty 16%
• Left Ventricular Function 8%
• Hypertension 8%
• Female Patients 8%
• Logistic Regression Analysis 8%
• Type 1 Diabetes Mellitus (T1DM) 8%
• Estrogen 8%
• Infarction 8%
• Cardiovascular Outcomes 8%
• Group-based 8%
• Current Smoking 8%
• Smoking Status 8%
• 3-flow 8%
• Acute ST-segment Elevation Myocardial Infarction 8%
• Comorbid Conditions 8%
• Coronary Revascularization 8%
• Contraceptives 8%
• Progestin 8%
• Oral Contraceptive Use 8%
• Age 50 8%
• Oral Contraceptive Therapy 8%
• Ethinylestradiol 8%
• Oral Contraception 8%
• Clinical Sequelae 8%

Medicine and Dentistry

• Myocardial Infarction 100%
• Adverse Outcome 100%
• Oral Contraceptive 100%
• Drospirenone 100%
• Drospirenone Plus Ethinylestradiol 46%
• Thrombus 23%
• Angioplasty 15%
• Infarction 7%
• ST Segment Elevation Myocardial Infarction 7%
• Diabetes Mellitus 7%
• Heart Left Ventricle Function 7%
• Cardiovascular System 7%
• Population Research 7%
• Ethinylestradiol 7%
• Sequela 7%
• Multivariate Logistic Regression Analysis 7%
• Oral Contraceptive Use 7%
• Gestagen 7%
• Oral Contraception 7%
• Heart Muscle Revascularization 7%

Pharmacology, Toxicology and Pharmaceutical Science

• Oral Contraceptive 100%
• Heart Infarction 100%
• Adverse Outcome 100%
• Drospirenone 100%
• Drospirenone Plus Ethinylestradiol 42%
• Thrombus 21%
• Population Study 7%
• ST Segment Elevation Myocardial Infarction 7%
• Infarction 7%
• Diabetes Mellitus 7%
• Ethinylestradiol 7%
• Progestin 7%